Invirase

RSS

saquinavir

Authorised
This medicine is authorised for use in the European Union.

Overview

Invirase is an antiviral medicine used to treat adults infected with the human immunodeficiency virus type 1 (HIV 1), a virus that causes acquired immune deficiency syndrome (AIDS). Invirase should only be used in combination with ritonavir (another antiviral medicine) and other antiviral medicines.

Invirase contains the active substance saquinavir.

This EPAR was last updated on 20/10/2022

Authorisation details

Product details
Name
Invirase
Agency product number
EMEA/H/C/000113
Active substance
saquinavir
International non-proprietary name (INN) or common name
saquinavir
Therapeutic area (MeSH)
HIV Infections
Anatomical therapeutic chemical (ATC) code
J05AE01
Publication details
Marketing-authorisation holder
Roche Registration GmbH
Revision
49
Date of issue of marketing authorisation valid throughout the European Union
03/10/1996
Contact address

Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Germany

Product information

17/10/2022 Invirase - EMEA/H/C/000113 - IB/0138

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Invirase is indicated for the treatment of HIV-1-infected adult patients. Invirase should only be given in combination with ritonavir and other antiretroviral medicinal products.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating
Average
1 rating